The report published in PNAS describes finding that, while alternatives to continuous breathing of 11 percent oxygen did not prevent symptom onset in a mouse model of Leigh syndrome - the most common pediatric mitochondrial disease - hypoxia therapy was able to reverse neurologic damage in animals close to the end stages of the disease.
"This is an extremely important next step in our exploration of the therapeutic potential of hypoxia for this neurodegenerative disease," says co-senior author of the report. "While hypoxia regimens that might have been more practical than the one we previously described were ineffective, we were excited to find that initiating 11 percent hypoxia treatment in mice on the brink of dying produced a complete reversal of both physiologic and behavioral symptoms. These stunning results provide hope that the brain lesions of Leigh syndrome may be reversible."
Genetic defects affecting mitochondria - subcellular structures that are essential to the conversion of nutrients into cellular energy - can have devastating effects in almost any organ system. With few exceptions, there are no effective treatments for mitochondrial diseases. Leigh syndrome is characterized by the development of lesions in the brain and produces neurodegenerative symptoms including muscular weakness and movement difficulties, loss of vision or hearing, and developmental delay. Symptoms usually appear in the first year of life and lead to death within two or three years.
In their 2016 study published in Science, the team first identified the potential of the hypoxia response to counteract genetic inhibition of the molecular reactions underlying mitochondrial function. They then showed that placing Ndufs4-knockout mice, an established model of Leigh syndrome, in an environment with 11 percent oxygen - about half of what is found at sea level - significantly reduced the development of typical symptoms and extended the animals' survival. A higher-than-normal oxygen environment of 55 percent accelerated death in the mouse model but had no effect on normal animals.
The current study was designed both to improve understanding of the effects of different oxygen levels on this mouse model and to see whether more practical hypoxia regimens might have results similar to those of the previous investigation. Imaging studies of Ndufs4-knockout mice raised in an 11 percent oxygen environment showed a complete lack of brain lesions at 250 days of life, while lesions appeared in less than 60 days in animals breathing 21 percent oxygen. While hypoxia-treated animals survived an average of 270 days, those raised in 21 percent oxygen only lived an average of 58 days. Breathing 55 percent oxygen led to rapid death of the Ndufs4-knockout mice from pulmonary edema, and the animals also developed lesions in the olfactory bulb of the brain.
Neither of two alternative hypoxia regimens - breathing 11 percent oxygen for only 10 hour a day or constantly breathing 17 percent oxygen - reduced or prevented the development of neurodegenerative symptoms in Ndufs4-knockout mice. Moving animals raised in an 11 percent environment into a 21 percent environment led to rapid symptom development and death, indicating the necessity of continuing treatment. However, moving 55-day-old mice raised in a 21 percent oxygen environment and already showing disease symptoms, including brain lesions, into an 11 percent oxygen environment produced rapid symptom improvement in as little as five days; and most of those animals were alive at 210 days of life.
While hypoxia treatment prevented brain disease in Ndufs4-knockout mice, it did not prevent the development of heart dysfunction, which appeared at around 150 days, well beyond the survival of untreated mice. Some Leigh syndrome patients develop a form of cardiomyopathy, and other mouse models in which Ndufs4 is knocked out only in cardiac tissue develop similar heart disease, suggesting the hypoxia treatment may have no effect on that symptom.
http://www.pnas.org/content/early/2017/05/03/1621511114.abstract?sid=ef236a41-0ef0-416f-b7d3-ccd56bff91ec
Hypoxia reverses mitochondrial disease in mouse model
- 1,549 views
- Added
Edited
Latest News
The assembly of the human c…
By newseditor
Posted 24 Apr
Wiring of the human neocortex
By newseditor
Posted 24 Apr
Abusive drugs hijack natura…
By newseditor
Posted 23 Apr
Mechanism of action of the…
By newseditor
Posted 23 Apr
Role of fat in rare neurolo…
By newseditor
Posted 23 Apr
Other Top Stories
The autonomic nervous system restores facial muscle function after…
Read more
The neurons that restore walking after paralysis
Read more
Exclusive white matter connectivity patterns in autism
Read more
High-fat diet can provoke pain sensitivity without obesity, diabetes
Read more
How nucleus accumbens mediates positive and negative motivational v…
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Hippocampus-to-amygdala pat…
By newseditor
Posted 24 Apr
Integrative spatial analysi…
By newseditor
Posted 24 Apr
Time-series reconstruction…
By newseditor
Posted 24 Apr
Harnessing gastrointestinal…
By newseditor
Posted 24 Apr
Sex-specific modulation of…
By newseditor
Posted 24 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar